作者:Nerea Gallastegui、Philipp Beck、Marcelino Arciniega、Robert Huber、Stefan Hillebrand、Michael Groll
DOI:10.1002/anie.201106010
日期:2012.1.2
Inhibitors with a new mechanism of action are needed for 20S proteasome (CP) inhibition owing to the ineffectiveness of current market drugs against some types of solid tumors. A novel class of nonpeptidic CP inhibitors has been developed, which display reversible and noncovalent binding. The structure‐based design of these highly active and site‐specific inhibitors revealed unexplored binding subpockets
由于目前市场上的药物对某些类型的实体瘤无效,因此需要具有新作用机制的抑制剂来抑制20S蛋白酶体(CP)。已经开发出一类新型的非肽CP抑制剂,其表现出可逆的和非共价结合。这些高活性和位点特异性抑制剂的基于结构的设计揭示了未探索的结合亚型。